{"id":54230,"date":"2026-02-23T22:13:03","date_gmt":"2026-02-23T22:13:03","guid":{"rendered":"https:\/\/www.globalresearch.co.kr\/insight\/neuroendocrine-tumor-treatment-market-mordor\/"},"modified":"2026-09-25T03:13:36","modified_gmt":"2026-09-24T18:13:36","slug":"neuroendocrine-tumor-treatment-market-mordor","status":"publish","type":"post","link":"https:\/\/www.globalresearch.co.kr\/insight\/neuroendocrine-tumor-treatment-market-mordor\/","title":{"rendered":"\uc138\uacc4\uc758 \uc2e0\uacbd\ub0b4\ubd84\ube44\uc885\uc591 \uce58\ub8cc \uc2dc\uc7a5 \uaddc\ubaa8 \ubc0f \uc810\uc720\uc728 \ubd84\uc11d – \uc131\uc7a5 \ub3d9\ud5a5 \ubc0f \uc608\uce21 (2026-2031\ub144)"},"content":{"rendered":"

\"Chart\"<\/p>\n

\"Chart\"<\/p>\n

\uff08\ub0b4\uc6a9\uc774 \ub108\ubb34 \uae38\uc5b4 \uc0dd\ub7b5\ub418\uc5c8\uc2b5\ub2c8\ub2e4.\uff09<\/p>\n","protected":false},"excerpt":{"rendered":"

\uc2e0\uacbd\ub0b4\ubd84\ube44\uc885\uc591(NET) \uce58\ub8cc \uc2dc\uc7a5\uc740 2025\ub144 28.9\uc5b5 \ub2ec\ub7ec\uc5d0\uc11c 2026\ub144 31\uc5b5 \ub2ec\ub7ec\ub85c \uc131\uc7a5\ud588\uc73c\uba70, 2026\ub144\ubd80\ud130 2031\ub144\uae4c\uc9c0 \uc5f0\ud3c9\uade0 \uc131\uc7a5\ub960(CAGR) 7.15%\ub97c \uae30\ub85d\ud558\uba70 2031\ub144\uc5d0\ub294 43.7\uc5b5 \ub2ec\ub7ec\uc5d0 \uc774\ub97c \uac83\uc73c\ub85c \uc804\ub9dd\ub429\ub2c8\ub2e4. \uc758\ub8cc\uc6a9 \ub3d9\uc704\uc6d0\uc18c, \ud2b9\ud788 \ub8e8\ud14c\ud2ac-177(Lutetium-177)\uc758 \uc0dd\uc0b0 \ub2a5\ub825 \uc99d\uac00\ub294 \uacfc\uac70\uc758 \uacf5\uae09 \ubcd1\ubaa9 \ud604\uc0c1\uc744 \ud574\uc18c\ud558\uc5ec \ubcd1\uc6d0\ub4e4\uc774 \ud3a9\ud0c0\uc774\ub4dc \uc218\uc6a9\uccb4 \ubc29\uc0ac\uc131\ud575\uc885 \uce58\ub8cc(PRRT)\ub97c 1\ucc28 \uce58\ub8cc \uc635\uc158\uc73c\ub85c \ucc44\ud0dd\ud560 \uc218 \uc788\uac8c \ud588\uc2b5\ub2c8\ub2e4. \ud5a5\ud6c4 PRRT \uc9c0\uce68, \ud76c\uadc0\uc758\uc57d\ud488 \uc778\uc13c\ud2f0\ube0c, \uae0d\uc815\uc801\uc778 NETTER-2 \uc784\uc0c1 \ub370\uc774\ud130\ub294 PRRT\uc758 \uc784\uc0c1\uc801 \uc218\uc6a9\ub3c4\ub97c \uc9c0\uc18d\uc801\uc73c\ub85c \ud655\ub300\ud558\uace0 \uc788\uc2b5\ub2c8\ub2e4. \ud22c\uc790\uc790\ub4e4\uc740 \uc218\uc9c1 \ud1b5\ud569\ub41c \ubc29\uc0ac\uc131\uc758\uc57d\ud488 \ud50c\ub7ab\ud3fc\uc5d0 \uc8fc\ubaa9\ud558\uace0 \uc788\uc73c\uba70, NETest\uc640 \uac19\uc740 \uc561\uccb4 \uc0dd\uac80 \uae30\uc220\uc740 \uc9c4\ub2e8\uc744 \uc815\uad50\ud654\ud558\uace0 \ud658\uc790\uc5d0\uac8c \uc801\ud569\ud55c \ud45c\uc801 \uce58\ub8cc\uc81c\ub97c \ub9e4\uce6d\ud558\ub294 \ub370 \uae30\uc5ec\ud558\uace0 \uc788\uc2b5\ub2c8\ub2e4. ITM\uc758 NOVA \uacf5\uc7a5\uacfc Curium\uc758 \ub124\ub35c\ub780\ub4dc \uc2dc\uc124\uacfc \uac19\uc740 \ub300\uaddc\ubaa8 \uac70\ub798\ub294 \ub3d9\uc704\uc6d0\uc18c \uacf5\uae09\ub9dd\uc774 \ud655\uc7a5\ub420 \uc218 \uc788\uc74c\uc744 \ubcf4\uc5ec\uc8fc\uba70 \uc758\ub8cc \uc2dc\uc2a4\ud15c\uc758 \uc2e0\ub8b0\ub97c \ub192\uc774\uace0 \uc788\uc2b5\ub2c8\ub2e4.<\/p>\n

\uc8fc\uc694 \ubcf4\uace0\uc11c \uc694\uc57d:
\n* \uce58\ub8cc \uc591\uc2dd\ubcc4: 2025\ub144 \uc18c\ub9c8\ud1a0\uc2a4\ud0c0\ud2f4 \uc720\uc0ac\uccb4(SSA)\uac00 \uc2e0\uacbd\ub0b4\ubd84\ube44\uc885\uc591 \uce58\ub8cc \uc2dc\uc7a5\uc758 43.62%\ub97c \ucc28\uc9c0\ud558\uba70 \uc120\ub450\ub97c \uc720\uc9c0\ud588\uc73c\uba70, PRRT\ub294 2031\ub144\uae4c\uc9c0 10.01%\uc758 CAGR\ub85c \uac00\uc7a5 \ube60\ub974\uac8c \uc131\uc7a5\ud560 \uac83\uc73c\ub85c \uc608\uc0c1\ub429\ub2c8\ub2e4.
\n* \uc801\uc751\uc99d\ubcc4: 2025\ub144 \uc704\uc7a5\uad00 \uc885\uc591\uc774 37.12%\ub85c \uac00\uc7a5 \ud070 \ube44\uc911\uc744 \ucc28\uc9c0\ud588\uc73c\uba70, \ucdcc\uc7a5 NET\ub294 2031\ub144\uae4c\uc9c0 11.45%\uc758 CAGR\ub85c \uac00\uc7a5 \ube60\ub974\uac8c \uc131\uc7a5\ud560 \uac83\uc73c\ub85c \uc804\ub9dd\ub429\ub2c8\ub2e4.
\n* \ucd5c\uc885 \uc0ac\uc6a9\uc790\ubcc4: 2025\ub144 \ubcd1\uc6d0\uc774 59.74%\ub85c \uac00\uc7a5 \ud070 \uc2dc\uc7a5 \uc810\uc720\uc728\uc744 \uae30\ub85d\ud588\uc73c\uba70, \uc678\ub798 \uc218\uc220 \uc13c\ud130\ub294 2031\ub144\uae4c\uc9c0 9.55%\uc758 CAGR\ub85c \uac00\uc7a5 \ube60\ub974\uac8c \uc131\uc7a5\ud560 \uac83\uc73c\ub85c \uc608\uc0c1\ub429\ub2c8\ub2e4.
\n* \uc9c0\uc5ed\ubcc4: 2025\ub144 \ubd81\ubbf8\uac00 39.35%\uc758 \uc810\uc720\uc728\ub85c \uc2dc\uc7a5\uc744 \uc8fc\ub3c4\ud588\uc73c\uba70, \uc544\uc2dc\uc544 \ud0dc\ud3c9\uc591(APAC) \uc9c0\uc5ed\uc740 2031\ub144\uae4c\uc9c0 9.86%\uc758 \uac00\uc7a5 \ub192\uc740 CAGR\uc744 \ubcf4\uc77c \uac83\uc73c\ub85c \uc608\uce21\ub429\ub2c8\ub2e4.<\/p>\n

\uae00\ub85c\ubc8c \uc2e0\uacbd\ub0b4\ubd84\ube44\uc885\uc591 \uce58\ub8cc \uc2dc\uc7a5 \ub3d9\ud5a5 \ubc0f \ud1b5\ucc30:<\/p>\n

\uc2dc\uc7a5 \ub3d9\uc778:
\n* NET \uc720\ubcd1\ub960 \uc99d\uac00 (+1.2% CAGR \uc601\ud5a5): \uc601\uc0c1 \uae30\uc220\uc758 \uc9c0\uc18d\uc801\uc778 \ubc1c\uc804\uacfc \uc778\uad6c \uace0\ub839\ud654\ub85c \uc778\ud574 NET \ubc1c\ubcd1\ub960\uc774 \uc99d\uac00\ud558\uace0 \uc788\uc2b5\ub2c8\ub2e4. \uc774\uc5d0 \ub530\ub77c \uc804\ubb38 NET \uc13c\ud130 \uc124\ub9bd \ubc0f \ub3d9\uc704\uc6d0\uc18c \uc0dd\uc0b0 \ub2a5\ub825 \ud655\ucda9\uc774 \uc774\ub8e8\uc5b4\uc9c0\uace0 \uc788\uc73c\uba70, \uc870\uae30 \uc9c4\ub2e8\uc774 \uac00\ub2a5\ud574\uc9c0\uba74\uc11c PRRT \ubc0f \ud45c\uc801 \uce58\ub8cc\uc81c \ud6c4\ubcf4\uad70\uc774 \ud655\ub300\ub418\uace0 \uc788\uc2b5\ub2c8\ub2e4.
\n* \uc601\uc0c1 \ubc0f \uc9c4\ub2e8 \uae30\uc220 \ubc1c\uc804 (+0.8% CAGR \uc601\ud5a5): NETest \uc561\uccb4 \uc0dd\uac80\uc740 \uae30\uc874 \ud06c\ub85c\ubaa8\uadf8\ub77c\ub2cc A(chromogranin A) \ubd84\uc11d\ubcf4\ub2e4 \ubbf8\uc138 \uc794\uc874 \uc9c8\ud658\uc744 \ub354 \uc815\ud655\ud558\uac8c \ucd94\uc801\ud558\uba70, \uace0\ud574\uc0c1\ub3c4 PET\/CT\uc640 \uacb0\ud569 \uc2dc \uc885\uc591 \uc0dd\ubb3c\ud559 \ubc0f \uce58\ub8cc \ubc18\uc751\uc5d0 \ub300\ud55c \uc2e4\uc2dc\uac04 \uc815\ubcf4\ub97c \uc81c\uacf5\ud558\uc5ec \uc9c4\ub2e8 \uc9c0\uc5f0\uc744 \ub2e8\ucd95\uc2dc\ud0b5\ub2c8\ub2e4.
\n* \uc2b9\uc778\ub41c \ud45c\uc801 \uce58\ub8cc\uc81c \ubc0f PRRT \uc57d\ubb3c \ud655\ub300 (+1.5% CAGR \uc601\ud5a5): Lutathera\uc758 EMA \uc2b9\uc778 \ubc0f \uae0d\uc815\uc801\uc778 NETTER-2 \uacb0\uacfc\ub294 PRRT\ub97c 1\ucc28 \uce58\ub8cc\ub85c \uc804\ud658\uc2dc\ucf30\uc73c\uba70, \uc18c\ub9c8\ud1a0\uc2a4\ud0c0\ud2f4 \uc720\uc0ac\uccb4\uc640 \ubcd1\uc6a9 \uc2dc \uc9c8\ubcd1 \uc9c4\ud589 \uc704\ud5d8\uc744 72% \uac10\uc18c\uc2dc\ud0a4\ub294 \ud6a8\uacfc\ub97c \ubcf4\uc600\uc2b5\ub2c8\ub2e4. Everolimus\ub294 \uc8fc\uc694 \ud45c\uc801 \uce58\ub8cc \uc635\uc158\uc73c\ub85c \ub0a8\uc544 \uc788\uc73c\uba70, Cabozantinib\uc740 \uc9c4\ud589\uc131 \uc9c8\ud658\uc5d0 \ub300\ud55c \uc120\ud0dd\uc9c0\ub97c \ub113\ud614\uc2b5\ub2c8\ub2e4.
\n* \ud76c\uadc0\uc758\uc57d\ud488 \uc778\uc13c\ud2f0\ube0c \ubc0f \uc6b0\ud638\uc801\uc778 \ubcf4\ud5d8 \uc218\uac00 (+0.9% CAGR \uc601\ud5a5): EU\uc758 10\ub144 \uc2dc\uc7a5 \ub3c5\uc810\uad8c\uacfc \ubbf8\uad6d\uc758 \uc9c4\ub2e8 \ubc29\uc0ac\uc131\uc758\uc57d\ud488\uc5d0 \ub300\ud55c \ucd94\uac00 \uc9c0\ubd88\uc740 \ud76c\uadc0 NET \uce58\ub8cc\uc81c \uac1c\ubc1c \uc704\ud5d8\uc744 \ub0ae\ucda5\ub2c8\ub2e4. EMA\uc758 \uac04\uc18c\ud654\ub41c \ud76c\uadc0\uc758\uc57d\ud488 \uacbd\ub85c\ub294 \ud6c4\uc18d \uc801\uc751\uc99d \uc2b9\uc778\uc744 \uac00\uc18d\ud654\ud558\uc5ec \uae30\uc5c5\ub4e4\uc774 \ub77c\ubca8 \uc801\uc6a9 \ubc94\uc704\ub97c \ub113\ud788\ub3c4\ub85d \uc7a5\ub824\ud569\ub2c8\ub2e4.<\/p>\n

\uc2dc\uc7a5 \uc81c\uc57d \uc694\uc778:
\n* \uc2e0\uaddc \uce58\ub8cc\uc81c\uc758 \ub192\uc740 \ube44\uc6a9 (-1.1% CAGR \uc601\ud5a5): Lutathera \uc8fc\uc785\uc740 \ucc28\ud3d0\ub41c \uc2dc\uc124, \ubc29\uc0ac\uc120 \ubaa8\ub2c8\ud130\ub9c1 \ubc0f \uc804\ubb38 \uc778\ub825\uc744 \ud544\uc694\ub85c \ud558\uc5ec \ucd1d \uce58\ub8cc \ube44\uc6a9\uc774 \uc57d\ubb3c \uac00\uaca9\uc744 \ud6e8\uc52c \uc0c1\ud68c\ud569\ub2c8\ub2e4. \uc720\ub7fd\uc758 \ubcf4\uac74 \uae30\uc220 \ud3c9\uac00 \uae30\uad00\ub4e4\uc740 \uce58\ub8cc\uc81c\ub97c \ucc98\ubc29 \ubaa9\ub85d\uc5d0 \ucd94\uac00\ud558\uae30 \uc804\uc5d0 \ube44\uc6a9-\ud6a8\uacfc\uc131(cost-per-QALY) \uacb0\uacfc\ub97c \uba74\ubc00\ud788 \uac80\ud1a0\ud569\ub2c8\ub2e4.
\n* \ub3d9\uc704\uc6d0\uc18c(Lu-177\/Ga-68) \uacf5\uae09 \ubcd1\ubaa9 \ud604\uc0c1 (-0.9% CAGR \uc601\ud5a5): ITM\uc758 NOVA \uacf5\uc7a5\uc774 \uc804 \uc138\uacc4 \ucd5c\ub300 \uc0dd\uc0b0\uc790\uc784\uc5d0\ub3c4 \ubd88\uad6c\ud558\uace0, \uc720\uc9c0\ubcf4\uc218 \uae30\uac04 \ub3d9\uc548 \uae00\ub85c\ubc8c \uc218\uc694\uac00 \uacf5\uae09\uc744 \ucd08\uacfc\ud558\ub294 \uacbd\uc6b0\uac00 \ubc1c\uc0dd\ud569\ub2c8\ub2e4.<\/p>\n

\uc138\uadf8\uba3c\ud2b8 \ubd84\uc11d:<\/p>\n

* \uce58\ub8cc \uc591\uc2dd\ubcc4: PRRT\uac00 \uc131\uc7a5 \ub3d9\ub825\uc73c\ub85c \ubd80\uc0c1
\n * \uc18c\ub9c8\ud1a0\uc2a4\ud0c0\ud2f4 \uc720\uc0ac\uccb4(SSA)\ub294 2025\ub144 \uc2e0\uacbd\ub0b4\ubd84\ube44\uc885\uc591 \uce58\ub8cc \uc2dc\uc7a5\uc758 43.62%\ub97c \ucc28\uc9c0\ud558\uba70 \uc99d\uc0c1 \uc870\uc808 \ubc0f \uc885\uc591 \uc548\uc815\ud654\uc5d0 \ub300\ud55c \uc624\ub79c \uc0ac\uc6a9\uc744 \ubc18\uc601\ud588\uc2b5\ub2c8\ub2e4.
\n * PRRT\ub294 [\u00b9\u2077\u2077Lu]Lu-Oxodotreotide\uc758 \ubcf4\ud3b8\uc801 \ucc44\ud0dd\uc5d0 \ud798\uc785\uc5b4 10.01%\uc758 CAGR\uc744 \uae30\ub85d\ud558\uba70 \uc8fc\uc694 \uc131\uc7a5 \ub3d9\ub825\uc73c\ub85c \ubd80\uc0c1\ud560 \uac83\uc73c\ub85c \uc608\uc0c1\ub429\ub2c8\ub2e4. \uc774\ud0c8\ub9ac\uc544 \ud575\uc758\ud559 \ud611\ud68c\uc758 \uc0c8\ub85c\uc6b4 \uc9c0\uce68\uc744 \ud1b5\ud574 PRRT \ud504\ub85c\ud1a0\ucf5c\uc774 \ud1b5\uc77c\ub418\uba74\uc11c \uc720\ub7fd \uc804\uc5ed\uc5d0\uc11c \ucc44\ud0dd\uc774 \ud655\ub300\ub418\uace0 \uc788\uc2b5\ub2c8\ub2e4.
\n * \ud604\uc7ac \uc784\uc0c1\uc801 \uc120\ud638\ub3c4\ub294 PRRT\uc640 \uc18c\ub9c8\ud1a0\uc2a4\ud0c0\ud2f4 \uc720\uc0ac\uccb4 \ubcd1\uc6a9 \uc694\ubc95 \ub610\ub294 PRRT\uc640 DNA \ubcf5\uad6c \uc5b5\uc81c\uc81c \ubcd1\uc6a9 \uc694\ubc95\uacfc \uac19\uc740 \ubcf5\ud569 \uc694\ubc95\uc73c\ub85c \uc804\ud658\ub418\uace0 \uc788\uc5b4 \uce58\ub8cc \ub300\uc0c1 \uc778\uad6c\uac00 \ud655\ub300\ub418\uace0 \uc788\uc2b5\ub2c8\ub2e4.
\n * Everolimus\uc640 Cabozantinib\uc774 \uc8fc\ub3c4\ud558\ub294 \ud45c\uc801 \uce58\ub8cc\ub294 \ubc29\uc0ac\uc131\ud575\uc885 \uce58\ub8cc\uc5d0 \ubd80\uc801\ud569\ud55c \ud658\uc790\uc5d0\uac8c \uac1c\ubcc4\ud654\ub41c \uc635\uc158\uc744 \uc81c\uacf5\ud558\uba70 \uc2dc\uc7a5\uc758 \ub2e4\uc591\ud654\ub97c \ubcf4\uc5ec\uc90d\ub2c8\ub2e4.<\/p>\n

* \uc801\uc751\uc99d\ubcc4: \ucdcc\uc7a5 NET\uac00 \ud601\uc2e0\uc744 \uc8fc\ub3c4
\n * \uc704\uc7a5\uad00 \uc885\uc591\uc740 2025\ub144 \uc2e0\uacbd\ub0b4\ubd84\ube44\uc885\uc591 \uce58\ub8cc \uc2dc\uc7a5\uc758 37.12%\ub97c \ucc28\uc9c0\ud588\uc73c\uba70, \uc774\ub294 \ud655\ub9bd\ub41c \uc784\uc0c1 \uacbd\ub85c\uc640 \uc18c\ub9c8\ud1a0\uc2a4\ud0c0\ud2f4 \uc720\uc0ac\uccb4\uc758 \uc77c\uc0c1\uc801\uc778 \uc0ac\uc6a9\uc5d0 \uae30\ubc18\ud569\ub2c8\ub2e4.
\n * \ucdcc\uc7a5 NET\ub294 2031\ub144\uae4c\uc9c0 11.45%\uc758 CAGR\uc744 \ubcf4\uc774\uba70 \uc131\uc7a5\uc744 \uc8fc\ub3c4\ud560 \uac83\uc73c\ub85c \uc608\uc0c1\ub418\uba70, Everolimus, Cabozantinib \ubc0f \uc774 \ud558\uc704 \uadf8\ub8f9\uc744 \ub300\uc0c1\uc73c\ub85c \ud558\ub294 PRRT \uc5f0\uad6c\uac00 \uc774\ub97c \ub4b7\ubc1b\uce68\ud569\ub2c8\ub2e4.
\n * \ud3d0 \ubc0f \ud749\uc120 NET \ub610\ud55c LEVEL \uc784\uc0c1 \uc2dc\ud5d8\uc5d0\uc11c \u00b9\u2077\u2077Lu-edotreotide\uc758 \uc7a0\uc7ac\uc801\uc778 \uc0dd\uc874 \uc774\uc810\uc774 \uac15\uc870\ub418\uba74\uc11c \uc5f0\uad6c \uad00\uc2ec\uc774 \ub192\uc544\uc9c0\uace0 \uc788\uc2b5\ub2c8\ub2e4.<\/p>\n

* \ucd5c\uc885 \uc0ac\uc6a9\uc790\ubcc4: \uc678\ub798 \uc218\uc220 \uc13c\ud130\uc758 \uc131\uc7a5 \uac00\uc18d\ud654
\n * \ubcd1\uc6d0\uc740 2025\ub144 \uc2e0\uacbd\ub0b4\ubd84\ube44\uc885\uc591 \uce58\ub8cc \uc2dc\uc7a5 \uc810\uc720\uc728\uc758 59.74%\ub97c \ucc28\uc9c0\ud588\ub294\ub370, \uc774\ub294 \uc790\uccb4 \ud575\uc758\ud559\uacfc \uc2dc\uc124\uacfc \ub2e4\ud559\uc81c \ud300 \ub355\ubd84\uc785\ub2c8\ub2e4.
\n * \uadf8\ub7ec\ub098 \uc678\ub798 PRRT \ud504\ub85c\ud1a0\ucf5c\uc740 \uc678\ub798 \uc218\uc220 \uc13c\ud130\ub85c\uc758 \uc804\ud658\uc744 \uac00\uc18d\ud654\ud558\uace0 \uc788\uc73c\uba70, \uc774 \uc13c\ud130\ub294 9.55%\uc758 CAGR\ub85c \uc131\uc7a5\ud560 \uac83\uc73c\ub85c \uc608\uc0c1\ub429\ub2c8\ub2e4. \uc774 \uc13c\ud130\ub4e4\uc740 \ud658\uc790 \uccb4\ub958 \uae30\uac04\uc744 \ub2e8\ucd95\ud558\uace0 \uac04\uc811\ube44\ub97c \uc808\uac10\ud558\ub294 \ud6a8\uc728\uc801\uc778 \uacbd\ub85c\ub97c \ud65c\uc6a9\ud569\ub2c8\ub2e4.<\/p>\n

\uc9c0\uc5ed\ubcc4 \ubd84\uc11d:<\/p>\n

* \ubd81\ubbf8: 2025\ub144 \uc2e0\uacbd\ub0b4\ubd84\ube44\uc885\uc591 \uce58\ub8cc \uc2dc\uc7a5\uc758 39.35%\ub97c \ucc28\uc9c0\ud558\uba70 \uc120\ub450\ub97c \ub2ec\ub838\uc2b5\ub2c8\ub2e4. \uace0\ube44\uc6a9 \ucd94\uc801\uc790\uc5d0 \ub300\ud55c Medicare\uc758 \ubcc4\ub3c4 \uc9c0\ubd88\uacfc FDA\uc758 \uc2e0\uc18d\ud55c \uc2b9\uc778 \uae30\ub85d\uc774 \uc870\uae30 \ucc44\ud0dd\uc744 \ub4b7\ubc1b\uce68\ud569\ub2c8\ub2e4. \uc8fc\uc694 \ubbf8\uad6d \uc554 \uc13c\ud130\ub4e4\uc740 \uc774\ubbf8 PRRT\ub97c \ud45c\uc801 \uce58\ub8cc\uc81c \ubc0f \uba74\uc5ed\uad00\ubb38\uc5b5\uc81c\uc81c\uc640 \ud1b5\ud569\ud558\uc5ec \uc784\uc0c1 \uc2dc\ud5d8\uc744 \uc9c4\ud589\ud558\uace0 \uc788\uc2b5\ub2c8\ub2e4.
\n* \uc720\ub7fd: EMA\uc758 \ud76c\uadc0\uc758\uc57d\ud488 \uacbd\ub85c\uc640 \ud76c\uadc0 \uc9c8\ud658 \uce58\ub8cc\uc81c \uc811\uadfc\uc744 \uac04\uc18c\ud654\ud558\ub294 \uc870\uc815\ub41c \uc9c0\ubd88 \uccb4\uacc4\uc758 \ud61c\ud0dd\uc744 \ubc1b\uc2b5\ub2c8\ub2e4. Curium\uc758 \ub124\ub35c\ub780\ub4dc Lu-177 \uc0dd\uc0b0 \ub77c\uc778\uacfc \uac19\uc740 \ud604\uc9c0 \ub3d9\uc704\uc6d0\uc18c \uc0dd\uc0b0 \ub2a5\ub825\uc740 \uacf5\uae09 \ubcf4\uc548\uc744 \uac15\ud654\ud569\ub2c8\ub2e4.
\n* \uc544\uc2dc\uc544 \ud0dc\ud3c9\uc591(APAC): 9.86%\uc758 \uac00\uc7a5 \ub192\uc740 CAGR\uc744 \uae30\ub85d\ud560 \uac83\uc73c\ub85c \uc608\uc0c1\ub429\ub2c8\ub2e4. \uc774\ub294 \uc77c\ubcf8\uc758 \uc9c4\ub2e8\uc81c \uc2e0\uc18d \uaddc\uc81c \uc2b9\uc778\uacfc \uc911\uad6d\uc758 \uc885\uc591\ud559 \uc778\ud504\ub77c \uad6c\ucd95\uc5d0 \ud798\uc785\uc740 \ubc14\uac00 \ud07d\ub2c8\ub2e4. \ud638\uc8fc\ub294 \uc758\uc57d\ud488 \ud61c\ud0dd \uc81c\ub3c4(Pharmaceutical Benefits Scheme)\uc5d0 \ub530\ub77c PRRT\ub97c \ubcf4\uc870\ud558\uba70, \ud55c\uad6d\uacfc \uc778\ub3c4\ub294 \uc720\ub7fd \ub3d9\uc704\uc6d0\uc18c \uae30\uc5c5\ub4e4\uacfc \ud30c\ud2b8\ub108\uc2ed\uc744 \uad6c\ucd95\ud558\uace0 \uc788\uc2b5\ub2c8\ub2e4.<\/p>\n

\uacbd\uc7c1 \ud658\uacbd:
\n\uc2e0\uacbd\ub0b4\ubd84\ube44\uc885\uc591 \uce58\ub8cc \uc2dc\uc7a5\uc740 \uae30\uc874 \uc81c\uc57d\uc0ac\uc640 \uc2e0\ud765 \ubc29\uc0ac\uc131\uc758\uc57d\ud488 \uc804\ubb38 \uae30\uc5c5 \uac04\uc758 \uacbd\uc7c1\uc73c\ub85c \uc778\ud574 \uc911\uac04 \uc815\ub3c4\uc758 \uc9d1\uc911\ub3c4\ub97c \ubcf4\uc785\ub2c8\ub2e4. Lantheus\ub294 \ub3d9\uc704\uc6d0\uc18c \uc0dd\uc0b0 \ubc0f \uc2e0\uaddc \ucd94\uc801\uc790 \ud655\ubcf4\ub97c \uc704\ud574 10\uc5b5 \ub2ec\ub7ec \uc774\uc0c1\uc744 \ud22c\uc790\ud588\uc2b5\ub2c8\ub2e4. Novartis\ub294 Lutathera \uc2dc\ud310 \ud6c4 \uc5f0\uad6c\ub97c \uc9c0\uc18d\ud558\uace0 \uc18c\ub9c8\ud1a0\uc2a4\ud0c0\ud2f4 \uc720\uc0ac\uccb4\uc640 \uc790\uc0b0\uc744 \uacb0\ud569\ud558\uba70 \ud575\uc2ec\uc801\uc778 \uc5ed\ud560\uc744 \uc720\uc9c0\ud558\uace0 \uc788\uc2b5\ub2c8\ub2e4. Ipsen\uc740 \uc9c4\ud589\uc131 NET\uc5d0\uc11c \uac15\ub825\ud55c 3\uc0c1 \ub370\uc774\ud130\ub97c \ubc14\ud0d5\uc73c\ub85c Cabozantinib \ub77c\uc774\uc120\uc2a4\ub97c \ud655\uc7a5\ud588\uc2b5\ub2c8\ub2e4. ITM, Curium, Eckert & Ziegler\uc640 \uac19\uc740 \uc804\ubb38 \uae30\uc5c5\ub4e4\uc740 \ub3d9\uc704\uc6d0\uc18c \ub18d\ucd95 \ubc0f \uc758\uc57d\ud488 \uc81c\uc870\ub97c \uc218\uc9c1 \ud1b5\ud569\ud558\uc5ec \ub9c8\uc9c4\uacfc \uacf5\uae09 \uc2e0\ub8b0\uc131\uc744 \ud655\ubcf4\ud558\uace0 \uc788\uc2b5\ub2c8\ub2e4. Crinetics\ub294 \uce74\ub974\uc2dc\ub178\uc774\ub4dc \uc99d\ud6c4\uad70\uc5d0 \ub300\ud55c \uacbd\uad6c\uc6a9 paltusotine\uc744 \uac1c\ubc1c\ud558\uc5ec \ube44\ubc29\uc0ac\uc131\uc758\uc57d\ud488 \ucc28\ubcc4\uc810\uc744 \ucd94\uac00\ud558\uace0 \uc788\uc2b5\ub2c8\ub2e4.<\/p>\n

\ucd5c\uadfc \uc0b0\uc5c5 \ub3d9\ud5a5:
\n* 2025\ub144 6\uc6d4: Ipsen\uc740 \uc9c4\ud589\uc131 \ucdcc\uc7a5 \ubc0f \ucdcc\uc7a5 \uc678 NET\uc5d0 \ub300\ud55c Cabometyx\uc5d0 \ub300\ud574 \uae0d\uc815\uc801\uc778 CHMP \uc758\uacac\uc744 \ubc1b\uc558\uc2b5\ub2c8\ub2e4.
\n* 2025\ub144 3\uc6d4: Exelixis\ub294 \uc774\uc804\uc5d0 \uce58\ub8cc\ubc1b\uc740 \uc131\uc778 \ubc0f \uccad\uc18c\ub144\uc758 \ubd84\ud654\ub3c4\uac00 \uc88b\uc740 \ucdcc\uc7a5 \ubc0f \ucdcc\uc7a5 \uc678 NET \ud658\uc790\uc5d0 \ub300\ud55c CABOMETYX\uc758 FDA \uc2b9\uc778\uc744 \ud68d\ub4dd\ud588\uc2b5\ub2c8\ub2e4.<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-54230","post","type-post","status-publish","format-standard","hentry","category-market-reports"],"_links":{"self":[{"href":"https:\/\/www.globalresearch.co.kr\/insight\/wp-json\/wp\/v2\/posts\/54230"}],"collection":[{"href":"https:\/\/www.globalresearch.co.kr\/insight\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.globalresearch.co.kr\/insight\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.globalresearch.co.kr\/insight\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.globalresearch.co.kr\/insight\/wp-json\/wp\/v2\/comments?post=54230"}],"version-history":[{"count":0,"href":"https:\/\/www.globalresearch.co.kr\/insight\/wp-json\/wp\/v2\/posts\/54230\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.globalresearch.co.kr\/insight\/wp-json\/wp\/v2\/media?parent=54230"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.globalresearch.co.kr\/insight\/wp-json\/wp\/v2\/categories?post=54230"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.globalresearch.co.kr\/insight\/wp-json\/wp\/v2\/tags?post=54230"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}